Tamoxifen citrate salt 

Protein kinase C inhibitor. Induces apoptosis in human malignant glioma cell lines. Tamoxifen and its metabolite 4-hydroxytamoxifen are selective estrogen response modifiers (SERMs) that act as estrogen antagonists in mammary gland. Blocks estradiol-stimulated VEGF production in breast tumor cells.

≥99%

human ... PRKCA(5578), PRKCB1(5579), PRKCD(5580), PRKCE(5581), PRKCG(5582), PRKCH(5583), PRKCI(5584)

2-8°C

Issandou, M., et al., Opposite effects of tamoxifen on in vitro protein kinase C activity and endogenous protein phosphorylation in intact MCF-7 cells. Cancer Res. 50, 5845-5850, (1990)

Gold, E., et al., Tamoxifen and norethisterone: effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat. Horm. Metab. Res. 26, 100-103, (1994)

Takei, H., et al., , In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 9, 39-42, (2002)

Schwartz, Z., et al., Tamoxifen elicits its anti-estrogen effects in growth plate chondrocytes by inhibiting protein kinase C. J. Steroid Biochem. Mol. Biol. 80, 401-410, (2002)

Powis, G., Signalling targets for anticancer drug development. Trends Pharmacol. Sci. 12, 188-194, (1991)

O'Brian, C.A., et al., Inhibition of protein kinase C by tamoxifen. Cancer Res. 45, 2462-2465, (1985)

3

KH2387000